

# MAIN PROGRAM



Website & Registration  
[www.imk.ch/sginf2016](http://www.imk.ch/sginf2016)

## Joint annual meeting 2016

Swiss Society for Infectious Diseases SSI

Swiss Society for Hospital Hygiene SSHH

Swiss Society of Tropical Medicine and Parasitology SSTMP

Swiss Specialists for Tropical and Travel Medicine FMH

**September 1-2, 2016**

Music & Convention Centre Montreux

[www.imk.ch/sginf2016](http://www.imk.ch/sginf2016)

# Kraftvoll. Robust. Ausdauernd.<sup>1-3</sup>



## Kraftvoll

Überlegene Wirksamkeit vs. LPV/r bei therapie-naiven Patienten gibt Vertrauen von Anfang an.<sup>1</sup>

## Robust

Hohe genetische Resistenzbarriere schützt den Backbone und hält Therapieoptionen offen.<sup>2</sup>

## Ausdauernd

Bemerkenswerte Langzeitdaten bestätigen gute Verträglichkeit und hohe Adhärenz.<sup>3,4</sup>

**PREZISTA<sup>®</sup>**  
darunavir

**Gekürzte Fachinformation Prezista:** Prezista<sup>®</sup> (Darunavirum, DRV) HIV-1-Proteasehemmer. I. Prezista<sup>®</sup> wird bei erwachsenen Patienten immer zusammen mit einem pharmakokinetischen Verstärker (Cobicistat oder niedrig dosiertem Ritonavir (RTV)) und zusätzlich anderen antiretroviralen Arzneimitteln zur Behandlung der HIV-Infektion eingesetzt. Bei vorbehandelten pädiatrischen Patienten ab 3 Jahren wird Prezista in Kombination mit niedrig dosiertem RTV eingesetzt. Prezista<sup>®</sup> soll ausschließlich von Ärzten verschrieben oder eingesetzt werden, die Erfahrung mit der Therapie HIV-infizierter Patienten besitzen. Die Anwendung soll nach Möglichkeit durch entsprechende genotypische oder phänotypische Untersuchungen und/oder durch die Vorgeschichte der verschiedenen Behandlungen gesteuert werden. D. Erwachsene ohne antiretrovirale Vorbehandlung: 1x täglich 800 mg DRV, zusammen mit 1x täglich 150 mg Cobicistat oder 100 mg RTV und Essen. Patienten mit antiretroviraler Vorbehandlung: A) Patienten ohne DRV-RAMs (siehe FI) und mit <100'000 HIV-1-RNA-Kopien/ml im Plasma und einer CD4+-Zellzahl von ≥ 200/10<sup>6</sup> Zellen/l: 1x täglich 800 mg DRV, zusammen mit 1x täglich 150 mg Cobicistat oder 100 mg RTV und Essen. B) Für alle anderen Patienten mit antiretroviraler Vorbehandlung oder Patienten ohne HIV-1-Genotypisierung: 2x täglich 600 mg DRV, zusammen mit 2x täglich 100 mg RTV und Essen. Die empf. Dosierung für Kinder mit Vorbehandlung basiert auf dem Körpergewicht (siehe Tabelle FI) und sollte die empfohlene Dosierung Prezista/RTV für Erw. (600 [6 ml]/100 mg 2x täglich) nicht überschreiten. Die Art der Nahrung beeinflusst die Exposition gegenüber DRV nicht. KI. Überempfindlichkeit gegenüber DRV oder Hilfsstoffen, schwere Niereninsuffizienz, schwere Leberfunktionsstörung (Child-Pugh Klasse C), Stillzeit. Arzneimittel mit stark von CYP3A4/CYP2D6 abhängiger Clearance (sowohl DRV, Cobicistat als auch RTV sind Hemmer des Cytochrom P450 3A4, [CYP3A4]-Isoenzym). Gleichzeitige Verabreichung mit: Antihistaminika, Alfuzosin, Sildenafil (zur Behandlung von pulmonaler arterieller Hypertonie), Colchicin, Antiarhythmika, Antiepi-

ptika, Ranolazin, Johanniskraut, Lovastatin, Mutterkornalkaloiden, Prokinetika, Neuroleptika, Sedativa und Hypnotika, PDE-5-Hemmern Vardenafil, Antipsychotika, Simvastatin, Rifampicin. VM: Kinder < 3 Jahre, Patienten > 65 Jahre. Sulfonamid Allergie oder Allergie gegen Gelborange S, schwerwiegende Hautreaktionen, schwere Leberfunktionsstörung, chronisch-aktive Hepatitis B oder C, Hepatotoxizität, Hämophilie Typ A und B, Hyperglykämie, Osteonekrose, Lipidstoffwechselstörungen, Immun-Rekonstitutionssyndrom, Arzneimittel-Interaktionen, Schwangerschaft, Stillzeit, Bedienen von Maschinen. UAW: Hypertriglyzeridämie, Hypercholesterinämie, erhöhte Leber- und Pankreasenzymspiegel, Durchfall, Übelkeit, Erbrechen, Kopfschmerzen, Bauchschmerzen, Hautausschlag. Weitere UAW und Laboranomalien siehe aktuelles Arzneimittel-Kompendium. IA: siehe KI und aktuelles Arzneimittel-Kompendium. Packungen: Erwachsene: 60 Filmtabletten zu 400 mg<sup>®</sup> (hellorange), 600 mg<sup>®</sup> (orange) und 30 Filmtabletten zu 800mg<sup>®</sup> (dunkelrot). Pädiatrie: 200 ml orale Suspension zu 100 mg/ml, 480 Filmtabletten zu 75 mg (weiss) und 240 Filmtabletten zu 150 mg (weiss). \*Kassenzulässig Abgabekategorie: Liste A. Ausführliche Informationen: www.swissmed.ch oder www.swissmedinfo.ch, Zulassungsinhaber: Janssen-Cilag AG, Gubelstrasse 34, 6300 Zug (PHCH/PRE/0316/0001)

**Referenzen:** 1 Orkin C. et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Medicine [2013], 14, 49-59. | 2 Eric Lefebvre and Celia A. Schiffer. Resilience to Resistance of HIV-1 Protease Inhibitors: Profi le of Darunavir. AIDS Rev. 2008; 10(3): 131-142. | 3 Mills A. M. et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009, 23:1679-1688. | 4 EACS Guidelines Version 8.0, October 2015

PHCH/PRE/0216/0002

## Table of Contents

Welcome to Montreux	4
General Information	5-8
Directions	9
Social Evening	10
<b>Program</b>	<b>11-23</b>
<b>Thursday, September 1, 2016</b>	
Daily Overview	11
Scientific Program	12-18
<b>Friday, September 2, 2016</b>	
Daily Overview	19
Scientific Program	20-23
Posters	24-35
Invited Speakers & Chairs	36
Industrial Exhibition   List of Exhibitors	40
Exhibition Plan	41
Meetings	42
Hall Overview	43

## Welcome to Montreux

Dear colleagues

On behalf of the Scientific Committee, it is our great pleasure to welcome you to Montreux for the Joint Annual Meeting 2016 of the Swiss Societies for Infectious Diseases (SSI), Hospital Hygiene (SSHH), Tropical Medicine and Parasitology (SSTMP) and the Swiss Specialists for Tropical and Travel Medicine FMH (SSTTM). The congress will take place in the multi-functional Music & Convention Centre in Montreux from Thursday, September 1st to Friday, September 2nd, 2016.

We are delighted to present an interesting and highly interdisciplinary program, including several renowned speakers. The conference also provides ample space for networking and exchange across traditional scientific boundaries. Besides the invited lectures, the program includes poster presentations, interactive case discussions, the much appreciated diagnostic quiz, special SSHH sessions with simultaneous translation as well as the general assemblies of the societies.

The main topics of the congress revolve around:

- Emerging infectious diseases and migration health
- Progress in the development and use of novel antibiotics
- HIV prevention and control
- Difficult to treat patients, difficult to prevent infections
- Innovation in infection prevention
- Update on protozoal infections
- Immunocompromised hosts, fungal infections and vaccines
- Intraabdominal infections

The format and venue of this Joint Annual Meeting provides a unique opportunity to interact and network with colleagues from various fields, to get in contact with renowned experts, and to visit the industrial exhibition.

We are looking forward to another successful and inspiring congress and to welcoming you to Montreux in September 2016!

For the scientific committee



Prof. Hansjakob Furrer, MD  
President SSI, Bern



Matthias Schlegel, MD  
President SSHH, St. Gallen



Prof. Christoph Hatz, MD  
President SSTM, Basel



Prof. Jürg Utzinger, PhD  
President SSTMP, Basel

## General Information

Date	September 1- 2, 2016
Congress venue	Music & Convention Centre Avenue Claude Nobs 5, 1820 Montreux, Switzerland <a href="http://www.2m2c.ch">www.2m2c.ch</a>
Congress secretariat	Thursday, September 1, 09:15–18:00 Friday, September 2, 07:00–16:30
Congress website	<a href="http://www.imk.ch/sginf2016">www.imk.ch/sginf2016</a>
Website of the societies	<a href="http://www.sginf.ch">www.sginf.ch</a> <a href="http://www.sgsh.ch">www.sgsh.ch</a> <a href="http://www.sstmp.ch">www.sstmp.ch</a> <a href="http://www.tropenmedizin-fmh.ch">www.tropenmedizin-fmh.ch</a>
Presidents	<b>Congress President</b>   SSI: Hansjakob Furrer, Bern SSHH: Matthias Schlegel, St. Gallen SSTMP: Jürg Utzinger, Basel SSTTM: Christoph Hatz, Basel
Scientific committee	Pietro Antonini   SSTTM Pierre-Yves Bochud   SSI Ursula Flückiger   SSI Hansjakob Furrer   SSI Christoph Hatz   SSTTM Laurent Kaiser   SSI Nicolas Müller   SSI Andri Rauch   SSI Laurence Rochat   SSTMP Matthias Schlegel   SSHH Jürg Utzinger   SSTMP Pietro Vernazza   SSI Andreas Widmer   SSI
Administrative secretariat	<b>IMK</b> Institute for medicine and communication Ltd Münsterberg 1, CH-4001 Basel Phone +41 61 271 35 51   Fax +41 61 271 33 38 <a href="mailto:congress@imk.ch">congress@imk.ch</a>   <a href="http://www.imk.ch">www.imk.ch</a>

## General Information

Registration	Early bird until July 17		Regular Jul 18–Aug 29		Onsite	
	2 days	1 day	2 days	1 day	2 days	1 day
Members (phys./academ.)	200.–	120.–	250.–	170.–	300.–	190.–
Non-Members (phys./academ.)	300.–	220.–	350.–	260.–	400.–	290.–
Members SSHH/nurses	140.–	80.–	170.–	110.–	200.–	130.–
Non-Members SSHH/nurses	160.–	100.–	190.–	130.–	220.–	160.–
Assistant doctors/students/ PhD/Post docs	140.–	80.–	170.–	110.–	200.–	130.–
Social evening (phys./academ.)	100.–					
Social evening Members SSHH, assistant doctors, nurses, students, Post docs, PhD	50.–					

**Cancellation fee** All cancellations must be faxed or electronically mailed to the administrative secretariat.  
 Cancellations received up to July 17th: 50% refund will be made  
 Cancellations received after July 17th: no refund will be made

**Participation confirmation** The participation confirmation will be distributed at the administrative secretariat during the congress.

**Credits** Credits have been confirmed by the following societies:

	01.09.2016	02.09.2016	Total
Swiss Society for Infectious Diseases   SSI	7 specific ID credits	7 specific ID credits	14 specific ID credits
Swiss Specialist Society for Tropical and Travel Medicine FMH	8 credits	8 credits	16 credits
Swiss Society of General Internal Medicine   SSGIM	6 credits	5.5 credits	11.5 credits
Swiss Association of Public Health Administration and Hospital Pharmacists   GSASA	50 Pkt.SP/KP	50 Pkt.SP/KP	100 Pkt.SP/KP

- Congress language**
- The official congress language is English.
  - Slides and presentations in the joint topics have to be in English.
  - Workshops, Posters, Posterflashes may be presented in English (preferred), but are possible in German or French.
  - SSHH presentations have to be in German or French.
  - Slides for all presentations have to be in English.

## General Information

-  **Simultaneous translation** Simultaneous translation German/French will be provided for several SSHH relevant sessions. The concerned sessions are marked accordingly in the program.
- Abstract publication** Accepted abstracts will be made available online in an abstract book shortly before the congress on the congress website.
- Poster** Format A0 portrait: 84.1cm x 118.9cm (width x height)  
Hang-up of the posters: Thursday, September 1, 2016, 09:30-12:00
- Posterflashes** Thursday, September 1, 2016, 15:45-17:15  
In addition to the poster in the poster exhibition some of the posters have been selected for a short oral presentation (of 5 minutes including discussion, max 3 slides) in the posterflash session.
- Posterwalk** SSI | SSTMP | SSTTM: Friday, September 2, 2016, 11:00-12:15  
SSHH: Thursday, September 1, 2016, 12:30-13:30  
The authors are requested to be present at their posters during this time.
- Information for speakers** Presentations have to be saved on an USB memory drive and delivered to the organizers in the conference room in the break before the precedent session.
- Awards SSHH**
- **Best poster**
  - **Best project (innovation/implementation)**
- Requirements for participation: At least the first or last author has to be member of the SSHH (individual or corporate) respectively has to have submitted the application for membership for the General Assembly 2016.
- Awards SSI | SAFE-ID** The Swiss Society for Infectious Diseases (SSI) and the Swiss Academic Foundation for Education in Infectious Diseases (SAFE-ID) will award 2 prizes each in the amount of CHF 15'000.00 for **outstanding scientific achievements in basic research and in clinical research** in infectious diseases during the 2016 annual meeting.  
[www.sginf.ch/about-us/awards-und-fellows/awards-und-fellows.html](http://www.sginf.ch/about-us/awards-und-fellows/awards-und-fellows.html)
- Accommodation** Please refer to Montreux-Vevy Tourisme to book your accommodation: Montreux-Vevy Tourisme  
Tel. +41 (0)84 886 84 84 | [info@montreuxriviera.com](mailto:info@montreuxriviera.com)

## General Information

We thank the following partner companies for their generous support:

### Premium partner 2016



### Partner 2016



### Supporter 2016



In addition, the following partners support the event for the following program\* parts:

HIV



New Antibiotics



Immunocompromized host, fungal infections and vaccines




Intraabdominal infections



\*sponsors have no influence on the scientific program

## General Information - Directions

Ideally located at the heart of Europe, one hour from Geneva Airport, easily and rapidly reached by road or rail, Montreux is in French-speaking Switzerland, facing the Alps and on the shores of Lake Geneva. Deep at the heart of Montreux, the Montreux Music & Convention Centre is right at the water's edge and just 5 minutes' walk from the town's station, hotels, restaurants, etc. Its location makes it easily reached by road or rail from major cities such as Geneva, Zurich, Paris or even Milan.



### Switzerland by plane

With two international airports, one in Geneva and the other in Zurich, Switzerland is a country that can be easily reached from anywhere in the world. Each airport has a road and rail link for Montreux.

Website of Geneva Airport: [www.gva.ch](http://www.gva.ch)

Website of Zurich Airport: [www.zurich-airport.com](http://www.zurich-airport.com)

### Montreux by car

- Geneva - Montreux: 1 hour
- Zurich - Montreux: 2 hours

Online route planner: [www.tcs.ch](http://www.tcs.ch)

### Montreux by train

- Geneva - Montreux: 1 hour
- Zurich - Montreux: 2 hours 30 minutes
- Lausanne - Montreux: 20 minutes

Timetable: [www.sbb.ch](http://www.sbb.ch)

## General Information - Social Evening

The social dinner will take place on **Thursday, September 1, 2016** starting from 19:00 at Chillon Castle, an architectural jewel located in the most beautiful setting imaginable - on the shores of Lake Geneva, right at the foot of the Alps. Offer yourself the pleasure of wandering through the courtyards and gardens and enjoying an evening in a fabulous ambiance and succumbing to the magic of this medieval monument.

### Address

Schloss Chillon

Avenue de Chillon 21, Veytaux/Montreux | [www.chillon.ch](http://www.chillon.ch)

### Tickets | Costs

Tickets can be purchased while registering for the congress.

Physicians | Academics: CHF 100.-

Members SSHH | Assistant doctors | Nurses | Students | Post docs | PhD: CHF 50.-



# Daily Overview | Thursday, September 1, 2016

	Salle Miles Davis V	Salles Stravinski II-IV	Salle Miles Davis VIII
10:15 - 10:30	Welcome 12		
10:30 - 11:00	Emerging infectious diseases and migration 12		
11:00 - 11:30			
11:30 - 12:00			
12:00 - 12:30	Lunch & *Posterwalk SSHH		
12:30 - 13:00	New antibiotics 12		Parasitic infections of the central nervous system 12
13:00 - 13:30			
13:30 - 13:45			
13:45 - 14:15	SSH session Implementation/innovation 13	HIV 15	
14:15 - 14:45			
14:45 - 15:15			
15:15 - 15:45	Coffee break		
15:45 - 16:15	Posterflashes 15		
16:15 - 16:45			
16:45 - 17:15			
17:15 - 17:30	Coffee break		
17:30 - 18:00	Awards SSHH 18	Awards SSI/Safe-ID 18	General assembly SSTTM 18
18:00 - 18:30	General assembly SSHH 18	General assembly SSI 18	
18:30 - 19:00			
from 19:00	Social evening		

-  Joint session
-  Break
-  SSTMP | SSTTM
-  SSI
-  SSHH
-  WS Workshop
-  Translation
-  Meeting (see meeting list on page 42)

\*Posterwalk SSHH 12:30-13:30

Poster exhibition: Miles Davis Hall  
 Industrial exhibition: Miles Davis Hall

## Thursday, September 1, 2016

10:15 - 10:30  
Salle Miles Davis V

### Welcome

Hansjakob Furrer, Bern

10:30 - 12:00  
Salle Miles Davis V



### Emerging infectious diseases and migration

Chairs: Hansjakob Furrer, Bern; Pietro Antonini, Lugano

10:30 - 11:00

#### Back to the future: return of the old antibiotics

Benedikt Huttner, Geneva

11:00 - 11:30

#### Diseases in migrants: clinical and diagnostical aspects

Francesco Castelli, Bescia, IT

11:30 - 12:00

#### Migration and infection control measurement in health care settings

Rein Jan Piso, Olten

12:00 - 12:30

Lunch

12:30 - 13:30

### Posterwalk SSHH

12:30 - 13:30  
Salle Miles Davis V

### New antibiotics

Chairs: Andreas Widmer, Basel; Christian van Delden, Geneva

12:30 - 13:00

#### Emerging antibiotic resistance: the additional menaces

Patrice Nordmann, Fribourg

13:00 - 13:30

#### New Antibiotics

Joseph S. Solomkin, Cincinnati OH, US

12:30 - 13:30  
Salle Miles Davis VIII

WS

### Parasitic infections of the central nervous system

Chair: Laurence Rochat, Lausanne

Bernhard Beck, Zurich

13:30 - 13:45

Lunch

13:45 – 15:15

Salle Miles Davis V



SSHH session

## Implementation/innovation

Chairs: Marie-Theres Meier, Zurich; Hugo Sax, Zurich

13:45 - 13:57

### **Simplifying the WHO-protocol: three steps versus six steps for performance of hand hygiene – a cluster randomized trial**

S. Tschudin-Sutter, D. Sepulcri, H. Gebreselassie, R. Frei, A. Widmer; Basel (CH)

13:58 - 14:10

### **Development and evaluation of double locus sequence typing for molecular epidemiological investigations of Clostridium difficile**

M. Stojanov, B. Magalhaes, V. Terletsky, P. Basset, G. Greub, L. Senn, D.S. Blanc; Lausanne (CH)

14:11 - 14:23

### **CleanHands – The Game. Händehygiene spielerisch lernen**

R. Kuhn, C. Kahlert, B. Pruzinova, B. Schöbi, R. Fulchini, M. Schlegel; St.Gallen (CH)

14:24 - 14:36

### **Patientenzone im Operationssaal am**

### **Universitäts Spital Zürich – Implementierung und Nachhaltigkeit**

H. Giger, A. Ebert, B. Pruzinova, J. Bender, H. Sax, S. Kuster; Zurich, St. Gallen (CH)

14:37 - 14:49

### **Automatische elektronische Echtzeit-Überwachung von nosokomialen Harnwegsinfektionen und Zentralvenenkatheter-assoziierten Bakteriämien am Universitäts Spital Zürich**

M. Dunic, P. Martic, C. Falk, J. Wehrli, M. Wenger, H. Sax, S. Kuster; Zurich (CH)

14:50 - 15:02

### **Coaching des médecins pour la prévention et le contrôle des infections: description d'une expérience pilote en médecine interne**

A. Kenfak, D. Hequet, J. Castioni, G. Waeber, G. Zanetti, L. Senn; Lausanne (CH)

15:03 - 15:15

### **Improving infection prevention and control at primary healthcare level in Tanzania through an innovative approach using an electronic tool**

S. Renggli, D. Mboya, I. Mayumana, C. Charles, C. Mshana, F. Kessy, T.R. Glass, C. Peiffer, B. VandeR. Plaetse, C. Lengeler; Basel (CH), Dar es Salaam (TZ), Ifakara (TZ), Basel (CH)

# DOLUTEGRAVIR

## CORE AGENT IN HIV THERAPY

- High efficacy<sup>1-5</sup>
- Favourable tolerability profile<sup>2,4,8,9</sup>
- High barrier to resistance<sup>2,4,6,7</sup>
- Few clinically significant DDIs (booster free)<sup>10</sup>



WWW.CH.DOLUTEGRAVIR.COM

Learn more  
about DTG  
based regimens  
with our medical  
experts.

Before initiating treatment with abacavir-containing products, HLA-B\*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B\*5701 allele due to the risk of hypersensitivity reaction.

**References:** 1. Walmsey SL, Antela A, Clumeck N, et al; for the SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med.* 2013;369(19):1807-18. 2. Walmsey et al. Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. *J Acquir Immune Defic Syndr.* 2015;70(5):515-9. 3. Clotet B, Feinberg J, van Lunzen J, et al; on behalf of the ING114915 Study Team. Once-daily Dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48-week results from the randomised open-label phase 3b study. *Lancet.* 2014;383:2222-31. 4. Molina JM, Clotet B, von Lunzen J, et al; on behalf of the FLAMINGO Study Team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96-week results from a randomised, open-label, phase 3b study. *Lancet HIV.* 2015;2(4):e127-36. 5. Cahn P, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV. *Lancet.* 2013; 382(9893): 700-708. 6. TIVICAY<sup>®</sup> Fächinformatio, 11.2015, www.swissmedinfo.ch. 7. Raffi F, Joeger H, Quiros-Roldan E, et al; on behalf of the extended SPRING-2 Study Group. Once-daily Dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96-week results from a randomised, double-blind, non-inferiority study. *Lancet Infect Dis.* 2013;13(11):927-35. 8. TRIUMEQ<sup>®</sup> Fächinformatio, 04.2016, www.swissmedinfo.ch. 9. Quercia R, Roberts J, Martin-Carpena L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. *Clin Drug Investig.* 35(3):211-9. 10. University of Liverpool. Drug interactions chart. July 2016. www.hiv-druginteractions.org (accessed July 2016).

**Triumeq<sup>®</sup> film coated tablets. A1:** Dolutegravir 50 mg, abacavir 600 mg, lamivudine 300 mg. **I:** Treatment of HIV infection in adults and adolescents from 12 years of age who are antiretroviral treatment-naive or are infected with HIV without documented or clinically suspected resistance to any of the three antiretroviral agents in Triumeq<sup>®</sup>. **D:** one tablet once daily (with or without food) in adults and adolescents weighing at least 40 kg. Triumeq<sup>®</sup> is a fixed-dose tablet and should not be prescribed to patients requiring dose adjustments (e.g. with a creatinine clearance below 50 ml/min). **CI:** Hypersensitivity to the active ingredients or to any of the excipients. Co-administration with dofetilide or pilsicainide. Moderate to severe hepatic impairment. **W/P:** Hypersensitivity reactions: Both abacavir and dolutegravir are associated with a risk of hypersensitivity reactions. A significantly increased risk for the occurrence of an abacavir hypersensitivity reaction is associated with carrying the HLA-B\*5701 allele. A reaction is also possible without HLA-B\*5701. HLA-B\*5701 status should be tested before starting treatment with abacavir. Patients known to carry HLA-B\*5701 should not use Triumeq<sup>®</sup>. Triumeq<sup>®</sup> must be discontinued immediately in the case of a suspected hypersensitivity reaction and must never be re-initiated (this also applies to any other medicinal product containing abacavir or dolutegravir). Monitor liver biochemistries in patients with hepatitis B and/or C co-infection. Careful monitoring required with concomitant metformin, consider metformin dose adjustment. Available data are inconclusive about a causal relationship between myocardial infarction and abacavir treatment. **IA:** Avoid co-administration of emtricitabine, zalcitabine, and medicinal products that reduce dolutegravir exposure (efavirenz, nevirapine, tipranavir/ritonavir, rifampicin and other enzyme-inducing medicinal products (St. John's wort, certain anti-epileptic drugs)). Administer dolutegravir 2 hours before or 6 hours after certain containing polyvalent cations (e.g. Mg, Al) or supplements containing calcium or iron. Co-administration with etravirine only in combination with lopinavir/ritonavir, darunavir/ritonavir or atazanavir/ritonavir. **P/L:** Triumeq<sup>®</sup> should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus. **AD:** Avoid breast-feeding. **AE:** Very common: Headache, diarrhoea, nausea, sleep disorders, fatigue. **Common:** Hypersensitivity reaction, anaemia, hyperglycaemia, hyperlipidaemia, insomnia, abnormal dreams, depression, dizziness, cough, nasal symptoms, upper abdominal pain or cramps, abdominal pain, abdominal discomfort, gastroesophageal reflux disease, dyspepsia, flatulence, skin rash, pruritus, alopecia, joint pain, muscle disorders, fever, lethargy, malaise. **Uncommon:** Neutropenia, anaemia, thrombocytopenia, immune reconstitution syndrome,

suicidal ideation or suicide attempt, hepatitis, transient hepatic enzyme elevation. **Rare:** Pancreatitis, rhabdomyolysis. **Very rare:** Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. **Sales category:** A. **Date of information:** April 2016. **ViiV Healthcare GmbH.** For more detailed information see [www.swissmedinfo.ch](http://www.swissmedinfo.ch). To report adverse drug events please contact [pv.swiss@gsk.com](mailto:pv.swiss@gsk.com).

**Tivicay<sup>®</sup> 50 mg film coated tablets. A1:** Dolutegravir. **I:** Treatment of HIV infection in adults and adolescents, in combination with other antiretroviral medicinal products. **D:** Adults: Patients without integrase-inhibitor-resistant HIV-1: 50 mg once daily. Patients with integrase-inhibitor-resistant HIV-1 (documented or clinically suspected): 50 mg twice daily. Adolescents above 12 years of age (weighing at least 40 kg) who have not previously been treated with an integrase inhibitor: 50 mg once daily. **CI:** Hypersensitivity to dolutegravir or to any of the excipients. Co-administration with dofetilide or pilsicainide. **W/P:** If signs or symptoms of hypersensitivity reactions develop, discontinue Tivicay<sup>®</sup> and other suspect agents immediately and monitor clinical status. If necessary appropriate therapy should be initiated. Liver biochemistry elevations consistent with Immune Reconstitution Syndrome were observed in some hepatitis B and/or C co-infected patients at the start of dolutegravir therapy. Monitoring of liver biochemistries in hepatitis B and/or C co-infection is recommended before starting treatment with Tivicay<sup>®</sup> and during treatment with Tivicay<sup>®</sup>. Careful monitoring required with concomitant metformin, consider metformin dose adjustment. Caution in severe hepatic impairment. **IA:** Avoid co-administration with enzyme inducers (e.g. anticonvulsants and St. John's wort). Administer dolutegravir 2 hours before or 6 hours after antacids containing polyvalent cations (e.g. Mg, Al) or calcium and iron supplements. Dose with 50 mg twice daily when co-administered with carbamazepine, efavirenz, nevirapine, tipranavir/ritonavir or rifampicin. Use with etravirine requires boosted PI or increased dose of dolutegravir. **P/L:** Dolutegravir should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus. **AD:** Avoid breast-feeding. **AE:** Very common: headache, diarrhoea, nausea. **Common:** Insomnia, dizziness, abnormal dreams, depression, vomiting, flatulence, upper abdominal pain, abdominal pain, abdominal discomfort, rash, pruritus, fatigue. **Uncommon:** Hypersensitivity, Immune Reconstitution Syndrome, suicidal ideation or suicide attempt, hepatitis. **Sales Category:** A. **Date of information:** November 2015. **ViiV Healthcare GmbH.** For more detailed information see [www.swissmedinfo.ch](http://www.swissmedinfo.ch). To report adverse drug events please contact [pv.swiss@gsk.com](mailto:pv.swiss@gsk.com).

## Thursday, September 1, 2016

13:45 – 15:15

Salles Stravinski II-IV

### HIV

Chairs: Pietro Vernazza, St. Gallen; Britta Lundström-Stadelmann, Bern

13:45 – 14:15

#### Global HIV situation

Matthias Egger, Bern

14:15 – 14:45

#### HIV therapy – one standard or many options?

Manuel Battegay, Basel

14:45 – 15:15

#### HIV: multi faceted options for prevention

Pietro Vernazza, St. Gallen

15:15 – 15:45

*Coffee Break*

15:45 – 17:15

Salle Miles Davis V

### Posterflashes

Chairs: Hansjakob Furrer, Bern; Matthias Schlegel, St. Gallen; Jürg Utzinger, Basel; Christoph Hatz, Basel

15:45 – 15:50

#### Decrease of pneumococcal meningitis associated with introduction of pneumococcal conjugate vaccination in Switzerland

W.C. Albrich, C. Hauser, M. Hilty; St. Gallen, Bern (CH)

15:50 – 15:55

#### Impact of MALDI-TOF mass spectrometry based identification directly from positive blood cultures on patient management: a randomized trial

M. Osthoff, N. Gürtler, S. Bassetti, G. Balestra, S. Marsch, H. Pargger, M. Weisser, A. Egli; Basel (CH)

15:55 – 16:00

#### Influence of time to diagnosis of severe influenza on antibiotic use, length of stay and mortality: a retrospective study

I.E. Akers, R. Weber, H. Sax, J. Böni, A. Trkola, S.P. Kuster; Zurich (CH)

16:00 – 16:05

#### A novel HIV-1-based vector that reproduces features of productive and latent HIV-1 infections

Y.L. Kok, S. Schmutz, V. Vongrad, M. Shilaih, A. Kelley, A. Inderbitzin, R. Kouyos, C. Berens, H.F. Günthard, K.J. Metzner; Zurich (CH), Jena (DE)

16:05 – 16:10

#### High rates of asymptomatic STIs in patients after primary HIV-1 infection

D.L. Braun, A. Marzel, D. Bircher, P. Schreiber, A. Scherrer, R. Kouyos, H. Günthard; Zurich (CH)

## Thursday, September 1, 2016

- 16:10 - 16:15 **The impact of HIV associated disorders (HAND) on cART adherence**  
S. Kamal, I. Locatelli, A. Sehat, M. Metral, O. Bugnon, R. Du Pasquier, M. Cavassini, M.P. Schneider; Geneva, Lausanne (CH)
- 16:15 - 16:20 **Identifying the etiology of undiagnosed respiratory infections in lung transplant recipients by unbiased metagenomic sequencing**  
D. Lewandowska, P. Schreiber, M. Schuurmans, B. Ruehe, O. Zagordi, C. Bayard, M. Greiner, F. Geissberger, R. Capaul, A. Zbinden, J. Böni, C. Benden, N. Mueller, A. Trkola, M. Huber; Lausanne (CH)
- 16:20 - 16:25 **Secular trends of bloodstream infections during neutropenia in 15,184 hematopoietic stem cell transplants: 13-year results from a European multicenter surveillance study (ONKO-KISS)**  
C. Theilacker, M. Weisser, S. Tschudin-Sutter, H. Bertz, M. Dettenkofer, W.V. Kern, A.W. Widmer; Basel (CH), Freiburg (DE)
- 16:25 - 16:30 **Clinical presentation and outcome of dengue in the native and expatriate communities of Dar es Salaam, Tanzania**  
N. Boillat-Blanco, B. Klaassen, L. Franco Narvaez, Z. Mbarack, J. Samaka, T. Mlaganile, A. Mamin, B. Genton, L. Kaiser, V. D'Acremont; Lausanne (CH), Dar es Salaam (TZ), Geneva (CH), Madrid (ES)
- 16:30 - 16:35 **Etiologies of acute febrile illness among HIV positive and HIV negative adults attending outpatient clinics in Dar es Salaam, Tanzania**  
N. Boillat-Blanco, Z. Mbarack, J. Samaka, T. Mlaganile, T. Kazimoto, A. Mamin, B. Genton, L. Kaiser, V. D'Acremont; Lausanne (CH), Basel (CH), Dar es Salaam (TZ)
- 16:35 - 16:40 **Campylobacter up, Salmonella down: an analysis of Swiss surveillance data, 1988–2013**  
C. Schmutz, D. Mäusezahl, M. Jost, A. Baumgartner, M. Mäusezahl-Feuz; Basel, Bern (CH)
- 16:40 - 16:45 **Systematic review of the level of compliance of health workers in Africa to the results of malaria rapid diagnostic tests**  
L.E. Coulter, V. D'Acremont; Lausanne, Basel (CH)

- 16:45 - 16:50 **Determinants of the effectiveness of mass dog vaccination to eliminate rabies in African cities**  
J. Zinsstag, M. Lechenne, M. Laager, M. Mindekem, M.S. Naïssengar, A. Oussigéré, K. Bidjeh, G. Rives, J. Tessier, D.M. Moto, I.O. Alfaroukh, Y. Muthiani, A. Traoré, J. Hattendorf, A. Lepelltier, H. Bourhy, L. Dacheux, T. Stadler; Basel (CH), N'Djaména (TD), Bamako (ML), Paris (FR), Lausanne (CH)
- 16:50 - 16:55 **Recent travelling to tropical or subtropical countries reduces the risk to suffer from travellers' diarrhoea in consecutive trips**  
E. Kuenzli, D. Juergensen, K. Kling, V.K. Jaeger, S. DeCrom, A. Neumayr, C. Hatz; Basel, Zurich (CH)
- 16:55 - 17:00 **Surveillance of the invasive Asian tiger mosquito (*Aedes albopictus*) in Switzerland**  
P. Müller, T. Suter, L. Engeler, V. Guidi, E. Flacio, M. Tonolla; Basel, Bellinzona (CH)
- 17:00 - 17:05 **Can we interpret hand hygiene compliance data over time?**  
E. Bucheli Laffer, N. Bartlomé, T. Erlanger, A. Limacher, A. Conen, C. Mohr, B. Müller, C.A. Fux; Aarau, Bern (CH)
- 17:05 - 17:10 **Massnahmen und Resultate nach einer Häufung orthopädischer postoperativer Wundinfekte**  
M. von Kietzell, S. Dogru-Wiegand, B. Schöbi, T. Kuhn, M. Schlegel; St. Gallen, Herisau (CH)
- 17:10 - 17:15 **Rapid MALDI-TOF mass-spectrometry-based detection of nosocomial *Rhizobium radiobacter* bloodstream infections from a common source**  
E. Lo Priore, C. Casanova, A. Egli, L. Räber, W. Steiger, M. Laguardia, S. Droz, J. Marschall, R. Sommerstein; Bern, Basel (CH)

## Thursday, September 1, 2016

17:30 – 18:00



**Awards SSHH**

Salle Miles Davis V

17:30 – 18:00

**Awards SSI/Safe-ID**

Salles Stravinski II-IV

18:00 – 19:00



**General assembly SSHH**

Salle Miles Davis V

18:00 – 19:00



**General assembly SSI**

Salles Stravinski II-IV

17:15 – 19:00



**General assembly SSTTM**

Salle Miles Davis VIII

*from 19:00*

*Social evening*

# Daily Overview | Friday, September 2, 2016

	Salle Miles Davis V	Salles Stravinski II-IV	
08:00 - 08:30			08:00 - 08:30
08:30 - 09:00	SSH session Infection control: how you did it		08:30 - 09:00
09:00 - 09:30	20	Difficult to treat 20	09:00 - 09:30
09:30 - 10:00	Coffee break		09:30 - 10:00
10:00 - 10:30	SSH session	Immunocompromized host, fungal infections and vaccines	10:00 - 10:30
10:30 - 11:00	News from outbreaks in Switzerland 20	21	10:30 - 11:00
11:00 - 11:30	Lunch & Posterwalk SSI   SSTMP   SSTTM		11:00 - 11:30
11:30 - 12:15			11:30 - 12:15
12:15 - 12:45	Intraabdominal infections		12:15 - 12:45
12:45 - 13:15			12:45 - 13:15
13:15 - 13:45	23		13:15 - 13:45
13:45 - 14:15	Coffee break		13:45 - 14:15
14:15 - 14:45		General assembly SSTMP	14:15 - 14:45
14:45 - 15:15	Diagnostic quiz	23	14:45 - 15:15
15:15 - 15:45	23		15:15 - 15:45
from 15:45	Closing remarks 23		from 15:45

- Joint Session
- Break
- SSTMP
- SSI
- SSHH
- Meeting  
(see meeting list on page 42)
- Translation

Poster exhibition: Miles Davis Hall  
 Industrial exhibition: Miles Davis Hall

## Friday, September 2, 2016

08:00 – 09:30

Salle Miles Davis V



SSHH session

### Infection control: how you did it

Moderation: Daniela Maritz, Basel; Marc Dangel, Basel

Experts: Members of the board SSHH

08:30 – 09:30

Salles Stravinski II-IV

### Difficult to treat

Chairs: Jonas Marschall, Bern; Barbara Hasse, Zurich

08:30 – 08:45

### Staphylococcus aureus – size matters

Annelies Zinkernagel, Zurich

08:45 – 09:00

### Prosthetic joint infections

Ilker Uçkay, Geneva

09:00 – 09:15

### Prosthetic vascular graft infections

Barbara Hasse, Zurich

09:15 – 09:30

### Infections with Candida forming biofilms

Stefan Zimmerli, Bern

09:30 – 10:00

Coffee Break

10:00 – 11:00

Salle Miles Davis V



SSHH session

### News from outbreaks in Switzerland

Chairs: Laurence Cuanillon, Lutry; Felix Fleisch, Chur

10:00 – 10:20

### Global *M. chimaera* outbreak in cardiac surgery – a systems check

Hugo Sax, Zurich

10:20 – 10:40

### Seek and you will find – a *Burkholderia cepacia* outbreak explained

Urs Führer, Biel; Jonas Marshall, Bern

10:40 – 11:00

### Iterative emergence of vancomycinresistant Enterococci

Laurence Senn, Lausanne

Friday, September 2, 2016

10:00 – 11:00

Salles Stravinski II-IV

**Immunocompromized host, fungal infections and vaccines**

Chairs: Pierre-Yves Bochud, Lausanne; Nicolas Müller, Zurich

10:00 – 10:30

**Transplantation in the time of multi-drug resistance**

Shirish Huprikar, New York, (NY)

10:30 – 11:00

**Funginos and STCS rapid fire talks**

10:30 – 10:35

**Funginos: Risk factors for mortality in candidemic patients**

Lauro Damonti, Lausanne

10:35 – 10:40

**Funginos: Mold infections in Switzerland**

Stefan Zimmerli, Bern

10:40 – 10:45

**STCS: Microbiome and lung transplantation**

Christian van Delden, Geneva

10:45 – 10:50

**STCS: The BKV study**

Hans H. Hirsch, Basel

10:50 – 10:55

**STCS: Vitamin D and infections**

Nicolas Müller, Zurich

10:55 – 11:00

**STCS: Infectious risk and host genetics**

Pierre-Yves Bochud, Lausanne

11:00 – 12:15

*Lunch*

11:00 – 12:15

**Posterwalk SSI | SSTMP | SSTTM**



because  
backbone  
matters<sup>1</sup>

Literature

1. Battegay, M. & Elzi, L. Does HIV antiretroviral therapy still need its backbone? *Lancet* 384, 1908-1910 (2014).

## Friday, September 2, 2016

**12:15 – 13:45**

Salle Miles Davis V

### **Intraabdominal infections**

Chairs: Ursula Flückiger, Aarau; Cédric Hirzel, Bern

12:15 – 12:37

### **New aspects and management of fungal peritonitis**

Thierry Calandra, Lausanne

12:37 – 12:59

### **Intra-abdominal parasitic infections: the clinician point of view**

Perry J.J. van Genderen, Rotterdam, NL

12:59 – 13:21

### **Viral hepatitis – update 2016**

Darius Moradpour, Lausanne

13:21 – 13:43

### **Surveillance and infection control in colon surgery**

Nicolas Troillet, Sion

13:45 – 14:15

*Coffee Break*

**14:15 – 15:15**

Salles Stravinski II-IV



### **General assembly SSTMP**

**14:15 – 15:45**

Salle Miles Davis V

### **Diagnostic quiz**

Chair: Ursula Flückiger, Aarau

**from 15:45**

Salle Miles Davis V

### **Closing remarks**

Hansjakob Furrer, Bern

## Posters

SSI: P01-P65, 89  
SSTMP: P58-P84  
SSTTM: P56-P58, P83-P88  
SSHH: P59, P89-113

\*Poster will be presented as a posterflash

- P01**      **Prospective, randomized comparison of one- versus two-stage bursectomy for moderate to severe septic bursitis**  
I. Uçkay, E. von Dach, B.A. Lipsky, D. Lew; Geneva (CH)
- P02**      **Should native septic joint arthritis be considered as immediate emergency?**  
I. Uçkay, N. Lauper, B.A. Lipsky, D. Lew; Geneva (CH)
- P03\***      **Decrease of pneumococcal meningitis associated with introduction of pneumococcal conjugate vaccination in Switzerland**  
W.C. Albrich, C. Hauser, M. Hilty; St. Gallen, Bern (CH)
- P04**      **Longer term safety of tenofovir alafenamide in renal impairment**  
F. Post, A. Clark, W. Short, M. Das, T. Edinger, M.W. Fordyce;  
London (GB), Brighton (GB), Philadelphia (US), Foster City (US), Zug (CH)
- P05**      **AIDS defining opportunistic infections (ADOIs) at unusually high CD4 counts below 500/ $\mu$ l: Is HIV the only problem? A chart review of the Swiss HIV Cohort Study (SHCS)**  
V. Gisler, M. Simsek, J. Nemeth, T. Lecompte, L. Merz, M. Stöckle, P. Schmid,  
E. Bernasconi, C. Fux, R. Weber, A. Calmy, M. Cavassini, H. Furrer;  
Bern, Zurich, Geneva, Lausanne, Basel, St. Gallen, Lugano, Aarau (CH)
- P06**      **An emerging infection: infective endocarditis after transcatheter aortic valve implantation (TAVI): a case series**  
G. Wyss, I. Moarof, C.A. Fux, A. Conen; Aarau (CH)
- P07\***      **Impact of MALDI-TOF mass spectrometry based identification directly from positive blood cultures on patient management: a randomized trial**  
M. Osthoff, N. Gürtler, S. Bassetti, G. Balestra, S. Marsch, H. Pargger, M. Weisser,  
A. Egli; Basel (CH)
- P08**      **First case of Legionella cincinnatiensis septic arthritis – case report and review of the literature**  
F. Banderet, A. Blaich, E. Soleman, V. Gaia, M. Osthoff; Basel, Bellinzona (CH)

## Posters

- P09** **A randomized, double-blind comparison of tenofovir alafenamide vs tenofovir disoproxil fumarate, each co-formulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 96 results**  
J. Fehr, H.J. Furrer, M. Cavassini, D. Wohl, S. Oka, N. Clumeck, A. Clarke, M. Das, H. Rovini, M. Fordyce; Zurich (CH), Bern (CH), Lausanne (CH), Chapel Hill (US), Tokyo (JP), Brussels (BE), Brighton (GB), Foster City (US), Zug (CH)
- P10** **Immunglobulin attenuate streptokinase-mediated virulence in necrotizing fasciitis by *Streptococcus disgalactiae* subspecies *equisimilis***  
F. Ugolini, F. Andreoni, N. Keller, A. Neff, E. Marques Maggio, A.S. Zinkernagel, R.A. Schuepbach; Zurich (CH)
- P11** **Pharmacokinetic-pharmacodynamic (PK-PD) of emtricitabine/tenofovir alafenamide (F/TAF) demonstrated wide exposure range associated with clinical safety**  
J. Custodio, L.S. Ting, J. Zack, M. Yan, L. Zhong, M.S. Rhee, J. Bruelle, B. Kearney; Foster City (US), Zug (CH)
- P12\*** **Influence of time to diagnosis of severe influenza on antibiotic use, length of stay and mortality: a retrospective study**  
I. E. Akers, R. Weber, H. Sax, J. Böni, A. Trkola, S.P. Kuster; Zurich (CH)
- P13** **Patient satisfaction in an outpatient parenteral antimicrobial therapy (OPAT) unit practising predominantly self-administration of antibiotics with elastomeric pumps**  
L. Saillen, L. Arensdorff, E. Moulin, R. Voumard, N. Boillat-Blanco, C. Gardiol, S. de Vallière; Lausanne (CH)
- P14** **Hepatitis C and the risk of non-liver-related morbidity and mortality in HIV+ persons**  
H. Kovari, A. Rauch, A. Calmy, P. Schmid, M. Cavassini, M. Stöckle, E. Bernasconi, R. Weber, B. Ledergerber; Zurich, Bern, Geneva, St. Gallen, Lausanne, Basel, Lugano (CH)
- P15** **Tenofovir alafenamide in HIV-infected patients with TDF-associated renal toxicity: a single centre experience**  
L.N. Walti, G. Wandeler, H. Rovini, A. Rauch, J. Steinrücken; Bern, Zug (CH)
- P16\*** **A novel HIV-1-based vector that reproduces features of productive and latent HIV-1 infections**  
Y.L. Kok, S. Schmutz, V. Vongrad, M. Shilaih, A. Kelley, A. Inderbitzin, R. Kouyos, C. Berens, H.F. Günthard, K.J. Metzner; Zurich (CH), Jena (DE)
- P17** **Highly sensitive droplet digital PCR to quantify the HIV-1 latent reservoir**  
V. Vongrad, Ch. von Siebenthal, H. Günthard, K. Metzner; Zurich (CH)
- P18** **Infectious complications after transplantation from donors with circulatory determination of death – a case-control study**  
M.V. Fehr, C. Benden, P. Dutkowsky, I. Inci, R. Lenherr, T. Müller, B. Müllhaupt, C. Oberkofler, O. De Rougemont, P. Schreiber, N. Müller; Zurich (CH)

## Posters

- P19\*** **High rates of asymptomatic STIs in patients after primary HIV-1 infection**  
D.L. Braun, A. Marzel, D. Bircher, P. Schreiber, A. Scherrer, R. Kouyos, H. Günthard; Zurich (CH)
- P20** **Antibiotics for preventing recurrent urinary tract infection: A meta-analysis**  
J. Steinrücken, A. Kuhn, A. Atkinson, J. Marschall; Bern (CH)
- P21** **Antimicrobial activity of *Lactobacillus salivarius* and *Lactobacillus fermentum* against *Staphylococcus aureus***  
M. Kang, J.M. Harro, M.E. Shirtliff, Y. Achermann; Baltimore (US), Zurich (CH)
- P22** **Implementing antimicrobial stewardship: one size does not fit all**  
M. von Kietzell, M. Schlegel, K. Boggian; St. Gallen (CH)
- P23** **How long do we need to hold cultures in bone and joint infections to isolate *Propionibacterium acnes*?**  
D. Bossard, B. Ledergerber, P. Zingg, C. Gerber, A.S. Zinkernagel, R. Zbinden, Y. Achermann; Zurich (CH)
- P24** **Long-term impact of late-onset cytomegalovirus replication on chronic lung allograft dysfunction and mortality in lung transplant recipients receiving antiviral prophylaxis**  
N. Jaamei, A. Koutsokera, J.A. Pasquier, M. Pascual, P. Meylan, J.D. Aubert, O. Manuel; Lausanne (CH)
- P25** **Missed opportunities for HIV diagnosis: data from patients newly presenting for HIV care at Lausanne University Hospital between 2010 and 2015**  
L. Lhopitallier, E. Moulin, M. Cavassini, K.E.A. Darling; Lausanne (CH)
- P26** **Investigating barriers in HIV-testing oncology patients: The IBITOP study phase II**  
T. Nguyen-Ngoc, M. Cavassini, L. Merz, S. Zimmermann, S. Peters, K.E.A. Darling; Lausanne (CH)
- P27** **Deficiency in sirtuin 2 increases bacterial phagocytosis by macrophages and protects from chronic staphylococcal infection**  
E. Ciarlo, T. Heinonen, M. Mombelli, J. Lugrin, B. Tyrrell, S. Lensh, H. Acha-Orbea, D. Le Roy, J. Auwerx, T. Roger; Lausanne (CH)
- P28** **The gut-derived short chain fatty acid propionate mediates anti-inflammatory activity but does not impact on host susceptibility to bacterial and fungal infections in vivo**  
E. Ciarlo, T. Heinonen, J. Herderschee, M. Mombelli, X. Zhang, D. Le Roy, T. Roger; Lausanne (CH)
- P29** **Which antibiotics reduce intracellular persisting *Staphylococcus aureus*?**  
N. Leimer, S. Götschi, C. Rachmühl, Y. Achermann, A.S. Zinkernagel; Zurich (CH)

## Posters

- P30** **Immunogenicity of standard vs. high dose of inactivated influenza vaccine in solid organ transplant recipients: a randomized controlled trial**  
M. Mombelli, N. Rettby, M. Perreau, M. Pascual, G. Pantaleo, O. Manuel; Lausanne (CH)
- P31** **Liver fibrosis in HIV-monoinfected persons with chronic elevated aminotransferase levels**  
M. Kälin, B. Ledergerber, B. Müllhaupt, A. Rauch, P. Schmid, F. Banderet, S. Giulieri, R. Weber, H. Kovari; Zurich, Bern, St. Gallen, Basel, Lausanne (CH)
- P32** **Decreased resistance to azithromycin in Gram-negative bacteria in eukaryotic growth medium**  
M. Meerwein, A. Tarnutzer, M. Hombach, A. Zinkernagel; Zurich (CH)
- P33** **Evaluating the impact of influenza vaccination on pneumococcal nasopharyngeal colonization in Canadian Hutterite children**  
D. Vuichar, D. Gysin, P. Singh, D. Mertz, K. Luinstra, J. Newton, E. Pullenayegum, M. Smieja, M. Loeb; Hamilton (CA), Basel (CH), Toronto (CA)
- P34** **Agreement between nasal mid-turbinate and nasopharyngeal swabs to detect *Streptococcus pneumoniae* by polymerase chain reaction in children and adults**  
D. Vuichard, P. Singh, K. Luinstra, J. Newton, M. Loeb, M. Smieja; Hamilton (CA)
- P35** **Detecting antimalarials in blood from community surveys in Tanzania**  
E. Pothin, J. Gallay, D. Mosha, M. Zuakulu, E. Lutahakana, L.A. Decosterd, B. Genton; Basel (CH), Dar es Salaam (TZ), Lausanne (CH)
- P36** **Treatment seeking behavior, diagnosis and treatment practices in Tanzania: comparison between community surveys conducted soon after the implementation of The Affordable Medicines Facility – malaria and the mRDTs roll out, and three years later**  
J. Gallay, IMPACT2 study team, B. Genton, E. Pothin; Basel (CH), Lausanne (CH), Dar es Salaam (TZ), London (GB), Atlanta (US)
- P37** **Method for the simultaneous measure of the level of nine antimalarial drugs in dried blood spot samples using LC-tandem mass spectrometry and relationship of lumefantrine concentrations in dried blood spot samples and in plasma**  
J. Gallay, E. Pothin, T. Mercier, S. Prod'hom, T. Buclin, B. Genton, L.A. Decosterd; Basel, Lausanne (CH)
- P38** **Staphylococcus aureus carriage at admission predicts early-onset pneumonia after burn trauma**  
A. Fournier, P. Eggimann, O. Pantet, M. Krähenbühl, C.L. Bonnemain, C. Fournier, E. Dupuis-Lozeron, J.L. Pagani, J.P. Revely, F. Sadeghipour, P. Voirol, Y. Que; Lausanne, Geneva, Bern (CH)

## Posters

- P39** **A pseudostratified human airway epithelial model with an air-liquid interface to study pneumococcal colonisation and invasive diseases**  
Kahlert, R. Dijkmann, S. Nigg, V. Thiel, L. Onder, J. Vidal, W. Albrich; St.Gallen (CH), Bern (CH), Atlanta (US)
- P40** **SOF/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: an integrated analysis of efficacy from the ASTRAL-1, ASTRAL-2 and ASTRAL-3 Studies**  
K. Agarwal, K. Patel, D. Samuel, M. Bourliere, Z.H. Younes, T.R. Morgan, S. Strasser, B. Leggett, C. Oberle, L. Liu, X. Ding, J. McNally, A. Osinusi, D.M. Brainard, J.G. McHutchison, N. Afdhal; London (GB), Toronto (CA), Villejuif (FR), Marseille (FR), Germantown (US), Long Beach (US), Camperdown (AU), Brisbane (AU), Foster City (US), Boston (US)
- P41\*** **The impact of HIV associated disorders (HAND) on cART adherence**  
S. Kamal, I. Locatelli, A. Sehat, M. Metral, O. Bugnon, R. Du Pasquier, M. Cavassini, M.P. Schneider; Geneva, Lausanne (CH)
- P42** **Population pharmacokinetics analysis of dolutegravir in HIV-1 infected individuals**  
M. Cavassini, M.P. Schneider; Lausanne (CH)
- P43** **Drug-drug interactions studies between HCV antivirals sofosbuvir and velpatasvir and HIV antiretrovirals**  
E. Mogalian, S. Naik, C. Oberle, J. Llewellyn, L. Stamm, A. Osinusi, G. Shen, K. Sajwani, J. McNally, A. Mathias; Lausanne (CH)
- P44\*** **Identifying the etiology of undiagnosed respiratory infections in lung transplant recipients by unbiased metagenomic sequencing**  
D. Lewandowska, P. Schreiber, M. Schuurmans, B. Ruehe, O. Zagordi, C. Bayard, M. Greiner, F. Geissberger, R. Capaul, A. Zbinden, J. Böni, 1C. Benden, N. Mueller, A. Trkola, M. Huber; Lausanne (CH)
- P45** **Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study**  
D. Wyles, N. Brau, S. Kottitil, E. Daar, K. Workowski, A. Luetkemeyer, O. Adeyemi, P. Ruane, B. Doehle, K.C. Huang, C. Oberle, A. Osinusi, J. McNally, D. Brainard, J.G. McHutchison, S. Naggie, M. Sulkowski; Lausanne (CH)
- P46** **The severity of infection determines the tonotopic localization of damage and extent of the resulting sensorineural hearing loss in experimental pneumococcal meningitis**  
M. Perny, M. Roccio, D. Grandgirard, M. Solyga, P. Senn, S.L. Leib; Bern, Geneva (CH)
- P47** **Adjuvant dexamethasone impairs the neuroregenerative capacity of the hippocampus in experimental infant rat pneumococcal meningitis**  
D. Grandgirard, L. Bally, S.L. Leib; Bern (CH)

## Posters

- P48** **High expression of macrophage migration inhibitory factor counterbalances the innate immune deficiencies of neonates**  
T. Roger, A. Schneider, M. Weier, F. Sweep, D. Le Roy, J. Bernhagen, T. Calandra, E. Giannoni; Lausanne (CH), Nijmegen (NL), Aachen (DE)
- P49\*** **Secular trends of bloodstream infections during neutropenia in 15,184 hematopoietic stem cell transplants: 13-year results from a european multicenter surveillance study (ONKO-KISS)**  
C. Theilacker, M. Weisser, S. Tschudin-Sutter, H. Bertz, M. Dettenkofer, W.V. Kern, A.W. Widmer; Basel (CH), Freiburg (DE)
- P50** **Microbiology of early-onset and late-onset bloodstream infections in neutropenic patients after high-dose chemotherapy: a prospective multicenter cohort study of 16,378 episodes of neutropenia**  
A.W. Widmer, M. Dettenkofer, K. Kaier, W.V. Kern, C. Theilacker; Basel (CH), Freiburg (DE)
- P51** **A new in-vitro bioassay for the detection of Clostridium botulinum neurotoxins**  
S.J. Jenkinson, D.G. Grandgirard, M.H. Heidemann, A.T. Tschertter, M.A. Avondet, S.L. Leib; Bern, Spiez (CH)
- P52** **Differential dynamics of HIV infection in MISTRG and MITRG mice**  
M.A. Rochat, L.D. Li, S.I. Ivic, A.A. Audigé, E.S. Schlaepfer, M.G.M. Manz, R.F.S. Speck; Zurich (CH)
- P53** **Host depletion sample preparation increases sensitivity of metagenomics analysis of cerebrospinal fluid samples of patients suffering from central nervous system infections**  
C.P. Oechslin, P. Agyeman, R. Bruggmann, L. Poveda, S.L. Leib, C.M. Beuret; Spiez, Bern, Zurich (CH)
- P54** **Imported infectious diseases among newly arrived Eritrean refugees in Basel – preliminary results from the Immigration Health Study Switzerland**  
A. Chernet, K. Kling, C. Hatz, K. Rentsch, A. Neumayr, N. Labhardt; Basel (CH)
- P55** **Daptomycin versus vancomycin in the treatment of infections with methicillin-resistant staphylococci or beta-lactam-resistant enterococci in neutropenic cancer patients: a pilot study**  
F. Tissot, N. Perrottet, L.A. Decosterd, T. Buclin, G. Prod'hom, C. Orasch, O. Marchetti, T. Calandra, V. Erard; Lausanne (CH)
- P56** **A prospective multicentre study of healthcare provider preference in rapid HIV testing kits: determine versus INSTI**  
N. Amyai, K.E.A. Darling, S. Ebert, E. Castro, V. D'Acremont, M. Monnat-Diseren, J. Perdrix, P. Bodenmann, A. Hérard Fossati, M. Cavassini; Lausanne (CH)

## Posters

- P57\*** **Clinical presentation and outcome of dengue in the native and expatriate communities of Dar es Salaam, Tanzania**  
N. Boillat-Blanco, B. Klaassen, L. Franco Narvaez, Z. Mbarack, J. Samaka, T. Mlaganile, A. Mamin, B. Genton, L. Kaiser, V. D'Acremont; Lausanne (CH), Dar es Salaam (TZ), Geneva (CH), Madrid (ES)
- P58\*** **Etiologies of acute febrile illness among HIV positive and HIV negative adults attending outpatient clinics in Dar es Salaam, Tanzania**  
N. Boillat-Blanco, Z. Mbarack, J. Samaka, T. Mlaganile, T. Kazimoto, A. Mamin, B. Genton, L. Kaiser, V. D'Acremont; Lausanne (CH), Basel (CH), Dar es Salaam (TZ)
- P59** **Legionnaires' disease in Switzerland: a look into the sparse literature**  
J. Giovanoli Evack, C. Schmutz, N. Gysin, D. Mäusezahl; Basel, Bern (CH)
- P60** **Prevalence of schistosomiasis in asylum seekers from sub-Saharan Africa**  
R.J. Piso, R. Pop, D. Zillig, R. Käch, U. Schibli; Olten, Bern (CH)
- P61** **Depletion of FoxP3+ regulatory T cells promotes T helper 1/17 cell immunity and leads to an improved control of larval Echinococcus multilocularis infection**  
J. Wang, R. Lin, M. Siffert, D.A. Vuitton, H. Wen, B. Gottstein; Bern (CH), Urumqi (CN), Besançon (FR)
- P62** **A dual PCR-based sequencing approach for the identification and discrimination of Echinococcus and Taenia**  
G. Boubaker, I. Marinova, M. Spiliotis, B. Gottstein; Bern (CH), Sofia (BG)
- P63** **Legionnaires' disease in Switzerland 1999 to 2015: strong increase of case numbers – causes unknown**  
N. Gysin, M. Jost, E. Altpeter, V. Gaia, C. Schmutz, D. Mäusezahl, M. Mäusezahl-Feuz; Bern, Bellinzona, Basel (CH)
- P64\*** **Campylobacter up, Salmonella down: an analysis of Swiss surveillance data, 1988–2013**  
C. Schmutz, D. Mäusezahl, M. Jost, A. Baumgartner, M. Mäusezahl-Feuz; Basel, Bern (CH)
- P65** **How common is acute gastroenteritis in primary care? Results from a study using the Swiss Sentinel Surveillance Network "Sentinella"**  
C. Schmutz, P.J. Bless, M. Jost, M. Mäusezahl-Feuz, D. Mäusezahl; Basel, Bern (CH)
- P66** **Evaluation of schistosomiasis Urine-CCA-Ag® in comparison to serology**  
R. Pop, D. Zillig, R. Käch, U. Schibli, B. Jamnicki, R.J. Piso; Bern, Olten (CH)

## Posters

- P67\*** **Determinants of the effectiveness of mass dog vaccination to eliminate rabies in African cities**  
J. Zinsstag, M. Lechenne, M. Laager, M. Mindekem, M.S. Naïssengar, A. Oussigéré, K. Bidjeh, G. Rives, J. Tessier, D.M. Moto, I.O. Alfaroukh, Y. Muthiani, A. Traoré, J. Hattendorf, A. Lepellitier, H. Bourhy, L. Dacheux, T. Stadler; Basel (CH), N'Djaména (TD), Bamako (ML), Paris (FR), Lausanne (CH)
- P68** **Development of a movement-based in vitro screening for new anti-cestodal compounds**  
D. Ritler, R. Rufener, J. Bouvier, H. Sager, A. Hemphill, B. Lundström-Stadelmann; Bern, St. Aubin (CH)
- P69** **Theileria annulata interacts with adaptor proteins of its bovine host cell**  
S. Huber, S. Rottenberg, K. Woods; Bern (CH)
- P70** **Drugs against alveolar echinococcosis: the hunt goes on**  
R. Rufener, L. Strübig, D. Ritler, A. Hemphill, B. Lundström-Stadelmann; Bern (CH)
- P71** **Ran as a potential effector for host cell transformation in Theileria annulata infected macrophages**  
A. Bär, S. Huber, A. Hemphill, K. Woods; Bern (CH)
- P72\*** **Recent travelling to tropical or subtropical countries reduces the risk to suffer from travellers' diarrhoea in consecutive trips**  
E. Kuenzli, D. Juergensen, K. Kling, V.K. Jaeger, S. DeCrom, A. Neumayr, C. Hatz; Basel, Zurich (CH)
- P73** **Evaluation of a commercial PCR based kit for the detection of parasitic protozoa in stools**  
M-L. Tritten, R. Lienhard, C. Parel, J. Schmid, H.H. Siegrist; La Chaux-de-Fonds (CH)
- P74** **New quantitative real-time PCR detecting Entamoeba moshkovskii in fresh stool samples**  
R. Wampfler, C. Stalder, H. Marti; Basel (CH)
- P75** **Immunization with Neospora caninum antigens fused to a TLR2 ligand increases pup survival in a nesporosis pregnant mouse model**  
A.P. Basto, A. Aguado-Martínez, L.T. Ryser, A. Leitão, A. Hemphill; Bern (CH) Lisbon (PT)
- P76** **Differential manipulation of the host cell Golgi and endosomal system by Toxoplasma gondii and a related apicomplexan, Besnoitia besnoiti**  
R. Cardoso, J. Wang, A. Hemphill; Bern (CH) Lisboa (PT)
- P77\*** **Surveillance of the invasive Asian tiger mosquito (Aedes albopictus) in Switzerland**  
P. Müller, T. Suter, L. Engeler, V. Guidi, E. Flacio, M. Tonolla; Basel, Bellinzona (CH)

## Posters

- P78**    **Molecular characterization and phylogeography of Fasciola flukes in Chad and Côte d'Ivoire**  
J. Giovanoli Evack, R.S. Schmidt, L. Achi, E. N'Goran, B. Bonfoh, I. Traoré, A. Adoum Batil, H. Greter, S.J. Krauth, J. Utzinger, J. Zinsstag, O. Balmer; Basel (CH), Bingerville (CI), Abidjan (CI), Korhogo (CI), N'Djamena (TD)
- P79**    **High prevalence of sub-microscopic malaria infections: relevance for control and elimination**  
H.P. Beck, N. Hofmann, R. Wampfler, F. Mwingira, I. Felger; Basel (CH)
- P80**    **Visceral leishmaniasis (kala-azar) in Eastern Sudan: treatment of 3500 patients with Médecins Sans Frontières' support**  
G. Alcoba, M.S. Elhag, M. Alnour, A. Atia, R. Anicete, F. Romero, P. Boulle, E. Sterk, M. Serafini, J.C. Cabrol, I. Ciglenecki, F. Chappuis; Geneva (CH), Khartoum (SD)
- P81**    **Diagnostic guidance for patients presenting with persistent fever in neglected tropical diseases endemic areas of Cambodia, Nepal and Sudan**  
F. Chappuis, B. Barbe, T. Phe, K. Koirale, K. Verdonck, J. Jacobe, S. EL. Safi, K. Lim, S. Rijal, M. Boelaert; Geneva (CH), Antwerp (BE), Phnom Penh (KH), Dharan (NP), Khartoum (SD)
- P82**    **Mining Sudanese medicinal plants for natural compounds against neglected tropical diseases**  
A. Babiker Mahmoud, P. Mäser, M. Kaiser, S. Khalid, S. Suleiman; Basel (CH), Khartoum (SD)
- P83\***    **Systematic review of the level of compliance of health workers in Africa to the results of malaria rapid diagnostic tests**  
L.E. Coulter, V. D'Acremont; Lausanne, Basel (CH)
- P84**    **Retrospective study on the utility of pulse oximetry for the identification of young children with severe illnesses and severe pneumonia in a rural outpatient clinic of Papua New Guinea**  
J. Blanc, I. Locatelli, P. Rarau, I. Muller, M. Gheri, B. Genton, N. Boillat-Blanco, N. Senn; Lausanne (CH), Madang (PG), Melbourne (AU)
- P85**    **Unpredictable checks of yellow fever vaccination certificates upon arrival in Tanzania**  
S. Schönenberger, C. Hatz, S. Bühler; Zurich, Basel (CH)
- P86**    **Stop measles in Switzerland – the importance of travel medicine**  
S. Bühler, P. Lang, B. Bally, C. Hatz, V.K. Jaeger; Zurich, Basel (CH)
- P87**    **Telemedicine for health problems while abroad: are travelers interested and willing to pay prior to departure?**  
L. Rochat, V. D'Acremont, B. Genton; Lausanne, Basel (CH)

## Posters

- P88** Enteropathogenic *Escherichia coli* (EPEC) infection detected by rapid multiplex panel detection after a yearlong course of persisting symptoms and unsuccessful investigations  
L. Rochat, G. Bessard, S. De Vallière; Lausanne (CH)
- P89** Application of whole genome sequencing to investigate a two year's *Pseudomonas aeruginosa* outbreak  
B. Magalhães, M.M.H. Abdelbary, F. Tissot, P. Basset, M. Berger, Y-A. Que, P. Eggimann, G. Prod'hom, G. Greub, G. Zanetti, L. Senn, D.S. Blanc; Lausanne (CH)
- P90** Hyperdrymist® micro-nebulized hydrogen peroxide: effectiveness in reducing *clostridium difficile* infections in a tertiary hospital after introduction as routine and preventive  
C. Garzoni, M. Ferrari, A. Bocconi, A. Agnesi; Lugano (CH), Bern (CH), Lodi (IT)
- P91** Added value of a transplant infectious diseases (TID) consultation for the diagnosis and prevention of infection in solid-organ transplant candidates  
A. Metsini, C. Berutto, J. Vionnet, P. Yerly, J.P. Venetz, P. Meylan, M. Pascual, O. Manuel; Lausanne (CH)
- P92** Surveillance des infections urinaires à entérobactéries productrices de beta lactamase à spectre élargi en EMS  
G. Gagnon, M. Attinger, I. Nahiman, A. Tessemo, C. Petignat; Lausanne (CH)
- P93** *Staphylococcus aureus* soft tissue infection may increase the risk of subsequent orthopaedic infections  
I. Uçkay, C. Bouvet, B.A. Lipsky, D. Lew; Lausanne (CH)
- P94** Low additive effect of inguinal swabs in MRSA and urine test in ESBL screening  
R. Käch, R. Pop, D. Zillig, U. Schbili, R.J. Plso; Olten, Bern (CH)
- P95** Delayed isolation precautions for varicella-zoster virus have minimal impact on health care workers: management and outcomes in a high-prevalence area  
F. Kessler, B. Lämmlli Millauer, P. Iseli, J. Marschall, R. Sommerstein; Bern (CH)
- P96** Zwei Jahre Influenza-Surveillance: Erfahrungen am Kantonsspital St. Gallen  
D. Flury, D. Nicca, R. Kuhn, B. Pruzinova, G. Rettenmund, K. Stiebeler, B. Schöbi, G. Dollenmaier, P. Vernazza, M. Schlegel; St. Gallen, Basel (CH)
- P97** Universal screening and decolonization for control of MRSA in nursing homes: follow-up to a cluster randomized controlled trial  
D. Héquet, V. Rousson, D. Blanc, C. Büla, L. Qalla-Widmer, E. Masserey, G. Zanetti, C. Petignat; Lausanne (CH)
- P98\*** Can we interpret hand hygiene compliance data over time?  
E. Bucheli Laffer, N. Bartlomé, T. Erlanger, A. Limacher, A. Conen, C. Mohr, B. Müller, C.A. Fux; Aarau, Bern (CH)

## Posters

- P99** **Routine testing and isolation for influenza based on a clinical case definition – staff compliance rather than epidemiologic background matters for success**  
E. Bucheli Laffer, N. Bartlomé, C. Ottiger, C.A. Fux; Aarau (CH)
- P100** **Spitalhygienische Aspekte beim Bau einer Milchküche**  
E. Rolli, A. Steiner, R. Munoz, J. Marschall; Bern (CH)
- P101** **CleanHands – successful implementation of a new module by Swissnoso**  
R. Fulchini, C. Kahlert, R. Kuhn, M. Schlegel, Swissnoso; St. Gallen (CH)
- P102** **Follow up results from the intervention study: change management with empowerment of nursing staff to reduce urinary catheter use**  
N. Bartlomé-Wyss, A. Conen, E. Bucheli Laffer, S. Schirlo, C.A. Fux; Aarau (CH)
- P103** **Fokusgruppeninterviews zu Ventilator-assoziierten Pneumonie und deren Prävention**  
M-T. Meier, A. Wolfensberger, L. Clack, M. Zollinger, H. Sax; Zurich (CH)
- P104** **Growth of Mycobacterium chimaera in heater-cooler units is not completely suppressed by an intensified cleaning and disinfection procedure**  
P. Schreiber, S. Kuster, B. Hasse, C. Bayard, C. Rüegg, P. Kohler, P. Keller, G. Bloemberg, R. Sommerstein, H. Sax; Zurich, Bern, Dübendorf (CH)
- P105\*** **Massnahmen und Resultate nach einer Häufung orthopädischer postoperativer Wundinfekte**  
M. von Kietzell, S. Dogru-Wiegand, B. Schöbi, T. Kuhn, M. Schlegel;  
St. Gallen, Herisau (CH)
- P106** **An MRSA outbreak with a rare spa type in a maternity ward in a low-prevalence setting: look beyond your neighbourhood**  
C. Gutmann, W.C. Albrich, R. Rüdlinger, E. Schönenberger, A.D. Sturm, A. Egli,  
M. Schlegel; St.Gallen, Will, Basel (CH)
- P107** **Results of an admission-screening for multidrug-resistant Gram-negative bacteria in St. Gallen, Switzerland**  
E. Lemmenmeier, M. Schlegel, B. Mani, W.C. Albrich; St. Gallen (CH)
- P108** **Extended-spectrum beta-lactamase producing Enterobacteriaceae among healthy pregnant women: preliminary results of an ongoing cross-sectional study**  
D. Vuichar, D. Gysin, S. Tschudin-Sutter, D. Huang, C. Granado, D. Mueller, D. Nogarth,  
M. Dangel, I. Hoesli, A.F. Widmer; Hamilton (CA), Basel (CH)
- P109\*** **The role of a surveillance program for successfully introducing peripherally inserted central catheters (PICC): a 2-year observational study in an academic hospital**  
E. Lo Priore, M. Fliedner, J.T. Heverhagen, U. Novak, J. Marschall; Bern (CH)

## Posters

- P110** **Rapid MALDI-TOF mass-spectrometry-based detection of nosocomial Rhizobium radiobacter bloodstream infections from a common source**  
E. Lo Priore, C. Casanova, A. Egli, L. Räber, W. Steiger, M. Laguardia, S. Droz, J. Marschall, R. Sommerstein; Bern, Basel (CH)
- P111** **Verwendung von Urinkathetern: Retrospektive Datenanalyse**  
P. Neumair, W.C. Albrich, M. Schwark, S. Henz, M. Schlegel; St. Gallen (CH)
- P112** **"We are not irresponsible": nurses perception of strategies to improve nosocomial influenza prevention**  
D. Nicca, M. Rasi, D. Flury, A. Ulrich, S. Engberg, M. Schlegel;  
Basel (CH), St.Gallen (CH), Pittsburgh (US)
- P113** **Whole-genome sequencing in real-time investigation of a vancomycin-resistant Enterococcus faecium outbreak at a tertiary care hospital**  
M.M.H. Abdelbary, C. Bertelli, G. Greub, D. Hequet, G. Zanetti, L. Senn, D. Blanc;  
Lausanne (CH)

## Invited Speakers & Chairs

Page

### A

- 12 **Pietro Antonini, MD**  
Ospedale Regionale di Lugano  
Malattie infettive  
Via Tesserete 46  
6900 Lugano, CH
- 15 **Prof. Manuel Battegay, MD**  
Universitätsspital Basel  
Klinik für Infektiologie & Spitalhygiene  
Petersgraben 4  
4031 Basel, CH
- 12 **Bernhard Beck, MD**  
Praxis für Tropen- und Reisemedizin  
am Bellevue  
Rämistrasse 3  
8001 Zürich, CH
- 21 **PD Pierre-Yves Bochud, MD**  
Centre Hospitalier Universitaire Vaudois  
Service des maladies infectieuses  
Rue du Bugnon 46  
1011 Lausanne, CH
- 23 **Prof. Thierry Calandra, MD**  
Centre Hospitalier Universitaire Vaudois  
Service des maladies infectieuses  
Rue du Bugnon 46  
1011 Lausanne, CH
- 12 **Prof. Francesco Castelli, MD**  
Università degli Studi di Brescia  
Clinica di Malattie infettive e tropicali  
P.le Spedali Civili 1  
25123 Brescia, IT
- 20 **Laurence Cuanillon**  
Infirmière cheffe  
Résidence Ilot du Parc SA  
Rte de Taillepiep 125  
1095 Lutry, CH

Page

### D

- 20 **Marc Dangel, MPH**  
Universitätsspital Basel  
Fachexperte für Infektionsprävention  
Petersgraben 4  
4031 Basel, CH
- 21 **Lauro Damonti, MD**  
Centre Hospitalier Universitaire Vaudois  
Service des Maladies Infectieuses  
Rue du Bugnon 46  
1011 Lausanne, CH
- 12 **Prof. Christian Van Delden, MD**  
21 Hôpitaux Universitaires de Geneva  
Service des Maladies Infectieuses  
Rue Gabrielle-Perret-Gentil 4  
1211 Geneva 14, CH
- 15 **Prof. Matthias Egger, MD, MSc**  
University of Bern  
Institute of Social and Preventive Medicine  
Hochschulstrasse 6  
3012 Bern, CH
- 20 **Felix Fleisch, MD**  
Kantonsspital Graubünden  
Infektiologie und Spitalhygiene  
Loëstrasse 170  
7000 Chur, CH
- 23 **Prof. Ursula Maria Flückiger, MD**  
Hirslanden Klinik Aarau  
Zentrum für Innere Medizin  
5000 Aarau, CH
- 20 **Urs Führer, MD**  
Spitalzentrum Biel  
Infektiologie, Innere Medizin  
Vogelsang 84  
2501 Biel, CH

### E

### F

## Invited Speakers & Chairs

### Page

- 12 **Prof. Hansjakob Furrer, MD**  
15 Inselspital  
23 Universitätsklinik für Infektiologie  
und Reisemedizin  
Freiburgstrasse 18  
3010 Bern, CH
- G**
- 23 **Perry J.J. van Genderen, MD, PhD**  
Harbour Hospital and Institute for  
Tropical Diseases  
Haringvliet 2  
3011 TD, Rotterdam, NL
- H**
- 20 **PD Barbara Hasse, MD**  
Universitäts Spital Zürich  
Klinik für Infektionskrankheiten  
und Spitalhygiene  
Rämistrasse 100  
8091 Zürich, CH
- 21 **Prof. Hans H. Hirsch, MD**  
Universität Basel  
Departement Biomedizin  
Petersplatz 10  
4051 Basel, CH
- 23 **Cédric Hirzel, MD**  
Inselspital  
Universitätsklinik für Infektiologie  
und Reisemedizin  
Freiburgstrasse 18  
3010 Bern, CH
- 15 **Prof. Christoph Hatz, MD**  
Swiss Tropical and Public Health Institute  
Medicine and Diagnostics  
Socinstrasse 57  
4002 Basel, CH
- 21 **Shirish Huprikar, MD**  
Mount Sinai Hospital  
Transplant Infectious Disease  
5 East 98th Street 12th Floor  
New York, NY 10029, US

### Page

- 12 **Benedikt Huttner, MD**  
Hôpitaux Universitaires de Geneva  
Service des Maladies Infectieuses et  
Service Prévention et Contrôle de l'Infection  
Rue Gabrielle Perret-Gentil 4  
1211 Genève, CH
- L**
- 15 **Prof. Britta Lundström-Stadelmann, PhD**  
Universität Bern  
Institut für Parasitology  
Länggass-Str. 122  
Postfach  
3012 Bern, CH
- M**
- 20 **Daniela Maritz**  
Kantonsspital Baselland  
Fachexpertin für Infektionsprävention  
Spitalhygiene  
4101 Basel, CH
- 20 **PD Jonas Marschall, MD**  
Inselspital  
Universitätsklinik für Infektiologie  
Freiburgstrasse 18  
3010 Bern, CH
- 13 **Marie-Therese Meier**  
Universitäts Spital Zürich  
Fachexpertin Infektionsprävention  
Klinik für Infektionskrankheiten &  
Spitalhygiene  
Rämistrasse 100  
8091 Zürich, CH
- 23 **Prof. Darius Moradpour, MD**  
Centre Hospitalier Universitaire Vaudois  
Service de gastro-entérologie et d'hépatologie  
Rue du Bugnon 44  
1011 Lausanne, CH
- 21 **Prof. Nicolas Müller, MD**  
Universitäts Spital Zürich  
Klinik für Infektionskrankheiten  
und Spitalhygiene  
Rämistrasse 100  
8091 Zürich, CH

## Invited Speakers & Chairs

Page

### N

- 12 **Prof. Patrice Nordmann, MD, PhD**  
Université de Fribourg  
Microbiologie Médicale et Moléculaire  
Rue A.-Gockel 3  
1700 Fribourg, CH

### P

- 12 **Rein Jan Piso, MD**  
Kantonsspital Olten  
Infektiologie  
Baslerstrasse 150  
4600 Olten, CH

### R

- 12 **Laurence Rochat, MD**  
Policlinique Médicale Universitaire de  
Lausanne  
Centre de Vaccination et Médecine des  
Voyages  
Rue du Bugnon 46  
1011 Lausanne, CH

### S

- 13 **PD Hugo Sax, MD**  
20 Universitäts Spital Zürich  
Klinik für Infektionskrankheiten  
& Spitalhygiene  
Rämistrasse 100  
8091 Zürich, CH

### Laurence Senn, MD

Centre Hospitalier Universitaire Vaudois  
Service de médecine préventive hospitalière  
Mont Paisible 18  
1011 Lausanne, CH

- 15 **Matthias Schlegel, MD**  
Kantonsspital St. Gallen  
Infektiologie/Spitalhygiene  
Rorschacher Stasse 95  
9007 St. Gallen, CH

- 12 **Joseph S. Solomkin, MD, FACS, FIDSA**  
OASIS Global  
6005 Given Rd  
Cincinnati OH 45243, US

Page

- 23 **Prof. Nicolas Troillet, MD**  
Hôpital du Valais  
ZIS - Sitten  
Abteilung für Infektionskrankheiten  
Avenue du Grand-Champsec 86  
1951 Sitten, CH

### U

- 20 **Ilker Uçkay, MD**  
Hôpitaux Universitaires de Geneva  
Service des Maladies Infectieuses  
Rue Gabrielle-Perret-Gentil 4  
1211 Geneva 14, CH

- 15 **Prof. Jürg Utzinger, PhD**  
Swiss Tropical and Public Health Institute  
Epidemiology and Public Health  
Socinstrasse 57  
4002 Basel, CH

### V

- 15 **Prof. Pietro Vernazza, MD**  
Kantonsspital St. Gallen  
Infektiologie/Spitalhygiene  
9007 St. Gallen, CH

### W

- 12 **Prof. Andreas Widmer, MD**  
Universitätsspital Basel  
Klinik für Infektiologie & Spitalhygiene  
Petersgraben 4  
4031 Basel, CH

### Z

- 20 **PD Stefan Zimmerli, MD**  
21 Inselspital  
Universitätsklinik für Infektiologie  
und Reisemedizin  
3010 Bern, CH

- 20 **Prof. Annelies Zinkernagel, MD**  
Universitäts Spital Zürich  
Klinik für Infektionskrankheiten  
und Spitalhygiene  
Rämistrasse 100  
8091 Zürich, CH

FIRST ANNOUNCEMENT



## Joint annual meeting 2017

Swiss Society of Microbiology SSM

Swiss Society for Infectious Diseases SSI

Swiss Society for Hospital Hygiene SSSH

Swiss Society of Tropical Medicine and Parasitology SSTMP

**30 August – 01 September 2017**

Congress Center MESSE Basel

[www.imk.ch/sginf2017](http://www.imk.ch/sginf2017)

## Industrial Exhibition

### Opening hours of the industrial exhibition

Thursday, September 1, 2016, 09:45–17:30

Friday, September 2, 2016, 07:30–16:00

### List of exhibitors

The following companies will support the meeting and present their products and services at the exhibition.


#### Alphabetical order

No.	Company
5	AbbVie AG
35	Alere GmbH
22a	Almedica AG
28	Astellas Pharma AG
29	Avidicare AB
21	AXON LAB AG
27	B. Braun Medical AG
8	Basilea Pharmaceutica International Ltd
38	Bristol-Myers Squibb SA
16	Ecolab (Schweiz) GmbH
15	epiNet AG
2	Gilead
10	Handinscan Kft.
9	IVF HARTMANN AG
4b	Janssen-Cilag AG
36	Laboratoire Osler
3	MSD Merck Sharp & Dohme AG
31	Pall (Schweiz) AG
7	Pfizer
30	Sandoz Pharmaceuticals AG
34	Schülke & Mayr AG
33	Tinovamed GmbH
1	ViiV Healthcare
32	ViiV Healthcare

#### By booth number

No.	Company
1	ViiV Healthcare
2	Gilead
3	MSD Merck Sharp & Dohme AG
4b	Janssen-Cilag AG
5	AbbVie AG
7	Pfizer
8	Basilea Pharmaceutica International Ltd
9	IVF HARTMANN AG
10	Handinscan Kft.
15	epiNet AG
16	Ecolab (Schweiz) GmbH
21	AXON LAB AG
22a	Almedica AG
27	B. Braun Medical AG
28	Astellas Pharma AG
29	Avidicare AB
30	Sandoz Pharmaceuticals AG
31	Pall (Schweiz) AG
32	ViiV Healthcare
33	Tinovamed GmbH
34	Schülke & Mayr AG
35	Alere GmbH
36	Laboratoire Osler
38	Bristol-Myers Squibb SA

# Exhibition Plan



**Thursday, September 1, 2016**

**Swiss Society for Infectious Diseases | SSI**

Board Meeting 08:30-10:00, Salle Miles Davis VII

General Assembly 18:00-19:00, Salles Stravinski II-IV

**Swiss Specialist Society for Tropical and Travel Medicine FMH | SSTTM**

Board Meeting 16:00-17:00, Salle Miles Davis XIII

General Assembly 17:15-19:00, Salle Miles Davis XIII

**Swiss Society for Hospital Hygiene | SSHH**

Board Meeting 09:00-10:30, Salle Miles Davis IX

General Assembly 18:00-19:00, Salle Miles Davis V

**Friday, September 2, 2016**


**Swiss Society for Tropical Medicine and Parasitology | STTMP**

Board Meeting 14:00-14:15, Salles Stravinski II-IV


General Assembly 14:15-15:15, Salles Stravinski II-IV

# Hall Overview

## Ground floor



## First floor





**Ecalta**<sup>®</sup>  
anidulafungin IV



- Einziges Echinocandin mit überlegener Wirksamkeit gegenüber Fluconazol bei invasiver Candidiasis\*<sup>2,3</sup>
- Wirksam gegen *Candida albicans* und «Non-*albicans*-Spezies»<sup>1,2,4</sup>
- Keine bekannten klinisch relevanten Arzneimittelinteraktionen<sup>1</sup>
- Keine Dosisanpassungen bei Leber-/Niereninsuffizienz<sup>1</sup>

1. Aktuelle Fachinformation auf [www.swissmedinfo.ch](http://www.swissmedinfo.ch)

2. Reboli AC et al. Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007; 356(24): 2472–2482.

3. EMA, Ecalta: EPAR – Scientific Discussion (2007): p. 18. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Scientific\\_Discussion/human/000788/WC500020676.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000788/WC500020676.pdf)

4. Ruhnke M et al. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect. 2012 Jul; 18(7): 680–687.

\*bei erwachsenen, nicht-neutropenischen Patienten

**Ecalta**<sup>®</sup> (Anidulafungin). **Indikationen:** Behandlung von Candidämie und invasiver Candidiasis bei nicht-neutropenischen erwachsenen Patienten. Ecalta wurde hauptsächlich bei Patienten mit Candidämie untersucht und nur bei einer begrenzten Anzahl an Patienten mit tiefen Candida-Infektionen bzw. Abszessen. Es wurden hauptsächlich Infektionen durch *Candida albicans* untersucht und nur eine geringere Anzahl von Patienten mit Infektionen durch nicht-*albicans* Species, v.a. *C. glabrata*, *C. parapsilosis* und *C. tropicalis*. Für Infektionen durch *C. krusei* liegen bisher nur limitierte hauptsächlich experimentelle Daten vor. **Dosierung:** Anfangsdosis: am 1. Tag eine einmalige Dosis von 200 mg verabreichen. Erhaltungsdosis: Danach einmal 100 mg täglich verabreichen. Die Behandlungsdauer hängt vom klinischen Ansprechen des Patienten ab. Im Allgemeinen sind antimykotische Behandlungen nach der letzten positiven Kultur für mindestens 14 Tage weiterzuführen. Die Behandlungsdauer von 35 Tagen sollte nicht überschritten werden. Maximale Infusionsgeschwindigkeit 1,1 mg/Minute (entspricht 1,4 ml/Minute bei Rekonstitution und Verdünnung gemäss Anleitung). **Kontraindikationen:** Überempfindlichkeiten gegen Inhaltsstoffe von Ecalta und anderen Arzneimitteln aus der Gruppe der Echinocandine (z.B. Caspofungin). Patienten mit seltener hereditärer Fruktoseintoleranz sollte dieses Arzneimittel nicht verabreicht werden. **Vorsichtsmassnahmen:** Schwangerschaft, Stillzeit, Fahrtüchtigkeit, Bedienen von Maschinen. Leberfunktionsstörungen, infusionsbedingte Reaktionen. **Interaktionen:** Anästhetika. **Unerwünschte Wirkungen:** Koagulopathie, Thrombozytopenie, anaphylaktische Reaktionen, anaphylaktischer Schock, Hypokaliämie, Hypomagnesiämie, Hyperkaliämie, Konvulsionen, Kopfschmerzen, Flushing, GI-Nebenwirkungen, Transaminasenerhöhung, erhöhte alkalische Phosphatase, Bilirubinерhöhung, erhöhte Gamma-Glutamyltransferase, Pruritus, Hautausschlag, erhöhtes Serumkreatinin, u.a. **Packungen:** Ecalta: Durchstechflasche mit 100 mg Pulver. Verkaufskategorie A. **Zulassungsinhaber:** Pfizer PFE Switzerland GmbH, Schärenmoosstrasse 99, 8052 Zürich. Ausführliche Informationen siehe Arzneimittel-Fachinformation unter [www.swissmedinfo.ch](http://www.swissmedinfo.ch). (V010)



**Pfizer – Ihr Antiinfektiva Partner**

